This month's "MS — The Practical Art" will interest those starting a new good laboratory practices (GLP) bioanalytical laboratory,
reassessing an existing laboratory, or revamping a "spirit-of-GLP" laboratory to full GLP status. Historically, mass spectrometers
have been used largely in drug discovery owing to their qualitative capabilities and have escaped rigorous regulation. This
is clearly no longer the case. Mass spectrometers are used increasingly as primary detectors in all facets of operations,
which led to a column in 2004 exploring the changing nature of validation: "Taming the Regulatory Beast: Regulation Versus
Functionalism" (1).
Many firms conducting internal accounting analyses find that performing GLP bioanalyses internally (as opposed to outsourcing
them to contract laboratories) saves time and money. This economic efficiency is particularly true for large-sample-number
studies because pricing tends to be based upon a per-sample method.
The principle rarely extends to contract laboratories performing small-sample-number studies, however, because smaller numbers
of samples often lack profit potential. Consequently, those laboratories sometimes delay a sponsor's small-sample-number studies
or assign them a lower priority. This frustrates pharmaceutical sponsors because early studies, no matter how small, can be
time-critical, as in the case of toxicology studies.
Compared with a contract laboratory, internal resources are held accountable more easily for timeliness and compliance. A
sponsor can always outsource, but a contract laboratory cannot always subcontract. Moreover, an internal resource that is
active in performing GLP bioanalysis knows the latest trends in compliance and cost effectiveness. For that reason, such a
resource is well-suited to managing external resources, expecting them to implement those trends.  Sidebar I: Seven major categories of work for the validation master plan
|
This column presents the key steps necessary to start up a new GLP bioanalytical laboratory. Many of the examples derive from
the contributors experience starting up the GLP bioanalytical facility at Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts).
A recent FDA audit of Millennium and a supported investigational new drug (IND) application succeeded without issue or official
action.
We recommend treating a spirit-of-GLP laboratory as you would a non-GLP laboratory to convert it to full GLP status. To begin
constructing a new GLP facility, we suggest you first put into effect a master plan (Sidebar I). The master plan should address
these major categories of work, with each category assigned its own manager and allocated its own resources:
- Standard operating procedures
- Installation, operational, and performance qualification (IQ, OQ, and PQ, respectively) of facilities, instrumentation, and
software
- Personnel selection, staffing, and training
- Quality control (QC) procedures and staffing
- Quality assurance
- Procedures and staffing
- Documentation and archival process
- Final gap analysis.